ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
The Predictive Effects of Atherogenic Indices and Remnant Cholesterol on Gestational Diabetes Mellitus Risk.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Circulating Levels of Remnant Cholesterol as Potential Biomarkers for Predicting Gestational Diabetes: A Systematic Review.Journal of diabetes research · 2026Pooled it
- Early characterization of pregnancy glycemic traits in gestational diabetes mellitus by plasma cell-free mRNA and non-coding RNA.Epigenetics · 2026Article
- Metabolic biomarkers in early detection of gestational diabetes mellitus: a prospective diagnostic accuracy study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to investigate the predictive effects of atherogenic indices and remnant cholesterol on the risk of GDM. Patients and Methods: This observational study was conducted based on the Hospital's clinical information system. A total of 6619 participants including 2054 GDM patients and 4565 controls were obtained. Serum lipid data, including triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) levels were collected. Atherogenic indices including TG/HDL-C, TC/HDL-C, and LDL-C/HDL-C, and remnant cholesterol were regarded as independent variables, and GDM was regarded as the dependent variable. Logistic regression analyses, nomogram analysis, decision curve analysis (DCA), and restricted cubic spline (RCS) analysis were applied to explore the impact of atherogenic indices and remnant cholesterol on GDM. Results: The prevalence of GDM was 31.03% in this study. In comparison to the 1st quartile, the 4th quartile levels of atherogenic indices and remnant cholesterols were significantly associated with increased risks of gestational diabetes mellitus (GDM). The odds ratios (OR) for these associations were as follows: OR = 1.66 (95% CI: 1.41, 1.96) for TG/HDL-C; OR = 1.47 (95% CI: 1.24, 1.73) for TC/HDL-C; OR = 1.47 (95% CI: 1.24, 1.73) for LDL-C/HDL-C; and OR = 1.39 (95% CI: 1.18, 1.64) for remnant cholesterol. The DCA results confirmed the reliable clinical utility of GDM prediction by atherogenic indices and remnant cholesterol. The RCS regression analysis revealed the nonlinear relationships between the atherogenic indices, remnant cholesterol and GDM. Conclusion: This study revealed the potential predictive effects of atherogenic indices and remnant cholesterol on GDM. These findings underscore the potential of routine lipid testing as a cost-effective strategy for the early identification and management of GDM in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.